Lactation-Safe Postpartum Hypertension Management: Curr. Probl. Cardiol., 2025 Review Highlights
Postpartum hypertension is effectively managed using lactation-safe first-line agents like nifedipine and enalapril, which, when combined with structured home monitoring, significantly reduce hospital readmission rates, as a recent review has shown.
These findings are published in October 2025, in the journal Current Problems in Cardiology.
The Clinical Challenge of Postpartum Cardiovascular Care
Hypertensive Disorders of Pregnancy (HDP) remain a leading cause of maternal illness and mortality worldwide. In the period following delivery, high blood pressure (BP) may persist, worsen, or present for the first time, posing a significant risk for emergency department visits and hospital readmissions within the first six weeks. Managing these patients is uniquely complex, as clinicians must achieve rapid blood pressure control while ensuring the safety of the infant during breastfeeding. Because the early post-discharge window carries a high risk for severe cardiovascular events, establishing clear therapeutic targets and medication preferences is vital for improving long-term maternal health outcomes.
Review Overview
The contemporary evidence synthesis, covering the period from January 2015 to August 2025, involved a rigorous analysis of randomized controlled trials (RCTs) and large comparative cohort studies. The analysis focused on 12 weeks of postpartum care for women with conditions such as preeclampsia or gestational hypertension. Researchers evaluated the compatibility of common antihypertensives with lactation, established standard treatment thresholds, and reviewed the impact of emerging care models on maternal-infant outcomes.
The key findings from the review include:
Dihydropyridine Calcium-Channel Blockers (DHP-CCBs), specifically Nifedipine and Amlodipine, along with Angiotensin-Converting Enzyme (ACE) inhibitors such as Enalapril, are confirmed as highly compatible first-line options for breastfeeding mothers.
Large-scale cohort data indicates that Nifedipine Extended-Release (ER) is associated with a lower risk of hypertension-related readmissions than Labetalol-only prescriptions at discharge.
Severe hypertension (defined as ≥ 160/110 mmHg) requires immediate urgent treatment using intravenous (IV) labetalol, hydralazine, or oral immediate-release nifedipine.
For persistent hypertension, oral therapy should be initiated or continued at levels of ≥ 150/100 mmHg, with a target BP of ≤ 140/90 mmHg in clinical settings or approximately ≤ 135/85 mmHg for home monitoring.
Clinical Relevance and Targeted Prevention
For practicing physicians, this review highlights that Nifedipine ER is preferred over Labetalol at discharge to significantly reduce hypertension-related readmissions. For breastfeeding, nifedipine, amlodipine, and enalapril are safe first-line choices, while atenolol must be avoided due to neonatal risks. Implementing remote home monitoring (POP-HT) and reviews within 3–10 days optimizes BP control, promotes reverse cardiac remodeling, and helps mitigate long-term risks such as device-related infections.
Reference
Alhazmi AM, Albulushi A. Targeted antihypertensive therapy after hypertensive pregnancy: Lactation-safe choices, treatment thresholds, and outcomes (2015–2025). Current Problems in Cardiology. 2025 Oct 10.
